Bon Secours Richmond Health System
Duloxetine To Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Bind, Placebo-Controlled Phase II To Phase III Study
Read more about this trial →A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor
Read more about this trial →NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Read more about this trial →A Randomized, Phase II Trial of Cabozatinib and Cabozaninib plus Nivolumab vs Standard Chemotherapy in Patients with previously treated NSCLC
Read more about this trial →A Phase III Randomized Study Comparing Perioperative Nivolumab vs Observation in Treating Patients with Renal Cell Carcinoma Undergoing Nephrectomy
Read more about this trial →Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)
Read more about this trial →Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Read more about this trial →(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Read more about this trial →A RANDOMIZED PHASE III TRIAL COMPARING AXILLARY LYMPH NODE DISSECTION TO AXILLARY RADIATION IN BREAST CANCER PATIENTS (CT1-3 N1) WHO HAVE POSITIVE SENTINEL LYMPH NODE DISEASE AFTER NEOADJUVANT CHEMOTHERAPY
Read more about this trial →Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Read more about this trial →